Nicholas Ronald Glover

USPTO Granted Patents = 13 (Patent Applications = 2)

CIPO Patents = 4

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 5.5

ph-index = 4

Forward Citations = 22(Granted Patents)

Location History:

Ontario, CA (2008 - 2014)
Oakville, CA (2011 - 2023)

Company Filing History:

Viventia Biotechnologies Inc.

patents

Years Active: 2008-2023

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11713352 - Immunotoxin for treating cancer (2023-08-01),

2. 11713351 - Immunotoxin for treating cancer (2023-08-01),

3. 10858429 - Methods for treating cancer using an immunotoxin (2020-12-08),

4. 9259484 - Methods for treating cancer using an immunotoxin (2016-02-16),

5. 9109223 - Methods for generating and screening fusion protein libraries and uses thereof (2015-08-18),

6. 8969540 - Tumor specific antibody (2015-03-03),

7. 8716234 - Cytotoxins comprising modified bouganin toxin for the treatment of cancer (2014-05-06),

8. 8697075 - Cancer specific antibody and cell surface proteins (2014-04-15),

9. 8545840 - Methods for treating cancer using an immunotoxin (2013-10-01),

10. 8383117 - CD44E tumor specific antibody (2013-02-26),

11. 8084576 - Cancer associated glucose transporter 8 variant (2011-12-27),

12. 7750136 - Modified bouganin proteins, cytotoxins and methods and uses thereof (2010-07-06),

13. 7339031 - Modified bouganin proteins, cytotoxins and methods and uses thereof (2008-03-04),

Title: Innovations of Nicholas Ronald Glover

Introduction

Nicholas Ronald Glover is a prominent inventor based in Oakville, Canada. He holds a total of 13 patents, showcasing his significant contributions to the field of medical technology, particularly in cancer treatment.

Latest Patents

One of his latest patents involves an immunotoxin for treating cancer. This invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer. The immunotoxin comprises a ligand that binds to a protein on the cancer cell, attached to a toxin that is cytotoxic to the cancer cell. Specifically, the invention is directed towards the use of Vb4-845, a recombinant immunotoxin that includes a humanized, MOC31-derived, single-chain antibody fragment fused to a truncated form of exotoxin A. The invention also encompasses combination therapy methods, which include the use of reduced dosages of chemotherapeutic agents for the prevention or treatment of cancer. Additionally, it covers formulations and methods for the direct administration of the recombinant immunotoxin to the carcinoma.

Career Highlights

Throughout his career, Nicholas Glover has worked with notable organizations such as Merck Patent GmbH and the University of Zurich. His work in these institutions has contributed to advancements in pharmaceutical and medical research.

Collaborations

Some of his coworkers include Jeannick Cizeau and Glen MacDonald, who have collaborated with him on various projects.

Conclusion

Nicholas Ronald Glover's innovative work in the field of cancer treatment through his patents demonstrates his commitment to advancing medical science. His contributions are significant in the ongoing fight against cancer, and his collaborations further enhance the impact of his inventions.

This text is generated by artificial intelligence and may not be accurate.